Navigation Links
Kineta to Present at Symposium on Pandemic Preparedness

SEATTLE, June 12, 2017 /PRNewswire/ -- Kineta, Inc., a biotechnology company focused on the development of novel immuno-therapies, today announced Kineta Vice President of R&D and Head of Virology Kristin Bedard has been invited to present at the Pandemic Preparedness for the Northwest and Beyond meeting sponsored by Life Science Washington.  This Symposium will be held on June 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference Center in Seattle, WA.

Dr. Bedard will be joined by other leaders in infectious disease research and the global health community in discussing new approaches to developing drugs and vaccines that will address future pandemic threats. She will present an overview of Kineta's portfolio and highlight LHF-535, Kineta's first in class antiviral for Lassa Hemorrhagic Fever as well as the company's vaccine adjuvant program.  

This symposium will discuss threat prediction models, new medical and pharmaceutical research, the role of animals in disease outbreaks along with the roles of local measures, citizens, and businesses in helping mitigate outbreaks.  

Click here to learn more about this event. 

Kineta, Inc. is an emerging biotech company that fills a void in the biopharmaceutical industry by efficiently advancing first in class immuno-therapies from discovery to proof of concept.  Kineta is developing a focused pipeline of novel therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. We actively collaborate with a broad array of private, government, biodefense and industry partners to advance our innovative research. For more information on Kineta, Inc. visit our website,

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta's plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy
(206) 378-0400

To view the original version on PR Newswire, visit:

SOURCE Kineta, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
2. Lillys Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS
3. DarioHealth to Present at the 7th Annual LD Micro Invitational
4. Hill-Rom to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
5. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
6. Endo to Present at Goldman Sachs 38th Annual Global Healthcare Conference
7. Zimmer Biomet Holdings to Present at 42nd Annual Deutsche Bank Securities Annual Health Care Conference
8. RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting
9. NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects
10. CRH Medical Corporation To Present at the Bloom Burton & Co. Healthcare Investor Conference
11. Astute Medical, Inc. Previews Scientific Presentation At Upcoming National Kidney Foundation Spring Clinical Meeting
Post Your Comments:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):